FIP-gts potentiate autophagic cell death against cisplatin-resistant urothelial cancer cells

Anticancer Research

Volumn 34, Issue 6, 2014, Pages 2973-2984

  Li, Jian Ri ^a,b   Cheng, Chen Li ^b   Yang, Wan Jung ^a   Yang, Chi Rei ^c   Ou, Yen Chuan ^a,c   Wu, Ming Ju ^b   Ko, Jiunn Liang ^a,d  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Apoptosis; Autophagy; Chemo resistant; Urothelial carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; BAFILOMYCIN A1; BECLIN 1; CASPASE 3; CHLOROQUINE; CISPLATIN; FUNGAL IMMUNOMODULATORY PROTEIN; FUNGAL PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GANODERMA TSUGAE; NONHUMAN; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; WESTERN BLOTTING; BLADDER TUMOR; CELL PROLIFERATION; CHEMISTRY; CHEMO-RESISTANT; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; GANODERMA; HUMAN; MALE; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TUMOR CELL CULTURE;

APOPTOSIS; AUTOPHAGY; CHEMO-RESISTANT; UROTHELIAL CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; BLOTTING, WESTERN; CELL PROLIFERATION; CISPLATIN; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLOW CYTOMETRY; FUNGAL PROTEINS; GANODERMA; HUMANS; MALE; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 84906309002     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Bellmunt J and Albiol S: Chemotherapy for metastatic or unresectable bladder cancer. Seminars in oncology 34: 135-144, 2007.
2. Pliarchopoulou K, Laschos K, and Pectasides D: Current chemotherapeutic options for the treatment of advanced bladder cancer: a review. Urol Oncol 31: 294-302, 2013.
3. Volpe A, Racioppi M, D'Agostino D, D'Addessi A, Marangi F, Totaro A, Pinto F, Sacco E, Battaglia S, Chiloiro G, and Bassi PF: Advanced bladder cancer: new agents and new approaches. A review. Urologic oncology 31: 9-16, 2013.
4. Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, Obasaju CK, Wang Y, Nicol SJ and Kaufman DS: Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 24: 3451-3457, 2006.
5. Dreicer R, Li S, Manola J, Haas NB, Roth BJ and Wilding G: Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. Cancer 110: 759-763, 2007.
6. Winquist E, Vokes E, Moore MJ, Schumm LP, Hoving K and Stadler WM: A Phase II study of oxaliplatin in urothelial cancer. Urologic oncology 23: 150-154, 2005.
7. Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD and Vogelzang NJ: Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. The lancet oncology 11: 861-870, 2010.
8. Li JR, Cheng CL, Yang CR, Ou YC, Wu MJ and Ko JL: Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux. Toxicology letters 220: 267-276, 2013.
9. Livesey KM, Tang D, Zeh HJ and Lotze MT: Autophagy inhibition in combination cancer treatment. Current opinion in investigational drugs (London, England: 2000) 10: 1269-1279, 2009.
10. O'Donovan TR, O'Sullivan GC and McKenna SL: Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics. Autophagy 7: 509-524, 2011.
11. Boh B, Berovic M, Zhang J and Zhi-Bin L: Ganoderma lucidum and its pharmaceutically active compounds. Biotechnology annual review 13: 265-301, 2007.
12. Sanodiya BS, Thakur GS, Baghel RK, Prasad GB and Bisen PS: Ganoderma lucidum: a potent pharmacological macrofungus. Current pharmaceutical biotechnology 10: 717-742, 2009.
13. Li Q, Wang X, Chen Y, Lin J and Zhou X: Cytokines expression induced by Ganoderma sinensis fungal immunomodulatory proteins (FIP-gsi) in mouse spleen cells. Applied biochemistry and biotechnology 162: 1403-1413, 2010.
14. Lin YL, Liang YC, Tseng YS, Huang HY, Chou SY, Hseu RS, Huang CT and Chiang BL: An immunomodulatory protein, Ling Zhi-8, induced activation and maturation of human monocyte-derived dendritic cells by the NF-kappaB and MAPK pathways. Journal of leukocyte biology 86: 877-889, 2009.
15. Lin CH, Hsiao YM, Ou CC, Lin YW, Chiu YL, Lue KH, Chang JG and Ko JL: GMI, a Ganoderma immunomodulatory protein, down-regulates tumor necrosis factor alpha-induced expression of matrix metalloproteinase 9 via NF-kappaB pathway in human alveolar epithelial A549 cells. Journal of agricultural and food chemistry 58: 12014-12021, 2010.
16. Hsin IL, Ou CC, Wu TC, Jan MS, Wu MF, Chiu LY, Lue KH and Ko JL: GMI, an immunomodulatory protein from Ganoderma microsporum, induces autophagy in non-small cell lung cancer cells. Autophagy 7: 873-882, 2011.
17. Liao CH, Hsiao YM, Hsu CP, Lin MY, Wang JC, Huang YL and Ko JL: Transcriptionally mediated inhibition of telomerase of fungal immunomodulatory protein from Ganoderma tsugae in A549 human lung adenocarcinoma cell line. Molecular carcinogenesis 45: 220-229, 2006.
18. Liao CH, Hsiao YM, Sheu GT, Chang JT, Wang PH, Wu MF, Shieh GJ, Hsu CP and Ko JL: Nuclear translocation of telomerase reverse transcriptase and calcium signaling in repression of telomerase activity in human lung cancer cells by fungal immunomodulatory protein from Ganoderma tsugae. Biochemical pharmacology 74: 1541-1554, 2007.
19. Liao CH, Hsiao YM, Lin CH, Yeh CS, Wang JC, Ni CH, Hsu CP and Ko JL: Induction of premature senescence in human lung cancer by fungal immunomodulatory protein from Ganoderma tsugae. Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association 46: 1851-1859, 2008.
20. Ling YH, Aracil M, Zou Y, Yuan Z, Lu B, Jimeno J, Cuervo AM and Perez-Soler R: PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and activation of death-associated protein kinase. Clinical cancer research: an official journal of the American Association for Cancer Research 17: 5353-5366, 2011.
21. Bjorkoy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, Stenmark H and Johansen T: p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. The Journal of cell biology 171: 603-614, 2005.
22. Matsunaga K, Saitoh T, Tabata K, Omori H, Satoh T, Kurotori N, Maejima I, Shirahama-Noda K, Ichimura T, Isobe T, Akira S, Noda T and Yoshimori T: Two Beclin 1-binding proteins, Atg14L and Rubicon, reciprocally regulate autophagy at different stages. Nature cell biology 11: 385-396, 2009.
23. Boya P, Reggiori F, and Codogno P: Emerging regulation and functions of autophagy. Nature cell biology 15: 713-720, 2013.
24. Kim SY, Song X, Zhang L, Bartlett DL, and Lee YJ: Role of Bcl-xL/Beclin-1 in Interplay between Apoptosis and Autophagy in Oxaliplatin and Bortezomib-induced Cell Death. Biochemical pharmacology 2014.
25. Kung HJ: Targeting tyrosine kinases and autophagy in prostate cancer. Hormones & cancer 2: 38-46, 2011.
26. Levine B and Kroemer G: Autophagy in the pathogenesis of disease. Cell 132: 27-42, 2008.
27. Mizushima N, Levine B, Cuervo AM and Klionsky DJ: Autophagy fights disease through cellular self-digestion. Nature 451: 1069-1075, 2008.
28. Lima RT, Martins LM, Guimaraes JE, Sambade C and Vasconcelos MH: Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer gene therapy 11: 309-316, 2004.
29. Marquez RT and Xu L: Bcl-2:Beclin 1 complex: multiple, mechanisms regulating autophagy/apoptosis toggle switch. American journal of cancer research 2: 214-221, 2012.
30. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, Cattoretti G and Levine B: Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. The Journal of clinical investigation 112: 1809-1820, 2003.
31. Bhutia SK, Dash R, Das SK, Azab B, Su ZZ, Lee SG, Grant S, Yacoub A, Dent P, Curiel DT, Sarkar D and Fisher PB: Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24. Cancer research 70: 3667-3676, 2010.
32. Boutin B, Tajeddine N, Vandersmissen P, Zanou N, Van Schoor M, Mondin L, Courtoy PJ, Tombal B and Gailly P: Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis. The Prostate 73: 1090-1102, 2013.
33. Chai CY, Huang YC, Hung WC, Kang WY and Chen WT: Arsenic salts induced autophagic cell death and hypermethylation of DAPK promoter in SV-40 immortalized human uroepithelial cells. Toxicology letters 173: 48-56, 2007.
34. Chen S, Rehman SK, Zhang W, Wen A, Yao L, and Zhang J: Autophagy is a therapeutic target in anticancer drug resistance. Biochimica et biophysica acta 1806: 220-229, 2010.
35. Hsin IL, Sheu GT, Jan MS, Sun HL, Wu TC, Chiu LY, Lue KH and Ko JL: Inhibition of lysosome degradation on autophagosome formation and responses to GMI, an immunomodulatory protein from Ganoderma microsporum. British journal of pharmacology 167: 1287-1300, 2012.